Tepha just produced this: US2014/010892
The present invention generally relates to compositions and implants comprising resorbable polymer fibers for the regeneration of tissue. The implants can be used in many types of surgery but are most suited to use in osteo and osteochondral defect repair, as well as ligament and tendon repair.
I have no idea whether or not people are being let go at the end of this week. Last I spoke to Investor Relations they relayed, "The terms of the 8K are still in force. Our primary focus is to implement the plan". SEC requirements compel MBLX to issue a 10Q by August 15. Most likely a few days before. THAT is the deadline that cannot be postponed. News can obviously occur sooner--especially if they feel that it is material--but we'll see if we have a viable company by that date.
The new CFO thing is really funny in the context of claiming an immediate IPO. I'm surprised his claim that MBLX didn't have FDA food approval yet wasn't what caused people to notice the willfully inaccuracies being posted.
In any event, I hope he is shorting substantially. While that play has played out well for those betting against mblx, I'm in this for high risk potential. The larger the short position the better for quick positive returns if Shuler/Strobeck/Oracle decide to replicate their past financing success.
Sentiment: Strong Buy
Okay another short success. Hitting $0.50 triggers me out for a third payday in two trading days. Now I sit and see what news before another trade.
I'm not a cheerleader of MBLX. I certainly had wished that they had secured financing earlier. But--to be blunt--dagiw is as clueless as myself, or for that matter anybody else, regarding what will occur next. "Too little too late"--really? Does dagiw have Shaulson's phone tapped? Does he have Strobeck's e mail account hacked? Of all those who are not insiders, dagiw knows for certain what will occur. We will soon know what will occur. It is inconceivable that this can drag out past the next Q. And unlike the arrogant one who spouts out about imminent IPOs and too little too late--I am certain that I do not know for certain what will unfold.
A new paper, entitled "Bio-based n-butanol prepared from poly-3-hydroxybutyrate: optimization of the reduction of n-butyl crotonate to n-butanol" has just been accepted for publication.
"Using metabolic engineering approaches, the biopolymer poly-3-hydroxybutyrate (P3HB) can be over-produced in organisms such as bacteria and plants. Thermolysis of P3HB, either in isolated form or within biomass, yields crotonic acid, a potential bio-derived platform chemical. Reduction of crotonic acid provides n-butanol, which has value as a fuel and as a commodity chemical. Herein, we report optimization work on the hydrogenation of the n-butyl ester of crotonic acid to n-butanol, and the potential of this chemistry to be incorporated into the production of bio-n-butanol from P3HB containing biomass."
Researchers from Metabolix Report Recent Findings in Butyric Acids (Mild pyrolysis of P3HB/switchgrass blends for the production of bio-oil enriched...
n 2014, we plan to continue to identify additional sources of grant funding while we advance research under our existing grants, focused primarily on increasing PHB production in switchgrass and developing a thermal conversion process to recover crotonic acid. We may also seek to establish alliances with industry partners to commercially exploit this platform and the intellectual property we have gained in our work in this area. However, there can be no assurance that we will be successful in establishing or maintaining suitable partnerships.
Being irritated with the messenger doesn't change the context in which the information is provided. Arguing over semantics does not change the state of MBLX. It is worthy to note though that Piper Jaffray used to be covering analysts for MBLX and no longer do so. On the other hand they appear to be in the public arena as supporting an IPO with a company in the same space as MBLX.
Interesting to note that Piper Jaffray were covering analysts until 2011 and MBLX presented at a number of their Investor Conferences over the years so they would know the market well. Just did a search on both MBLX and PJ.
Meredian prepares for potential IPO
POSTED BY DORIS DE GUZMAN ⋅ JULY 25, 2014 ⋅ LEAVE A COMMENT
FILED UNDER PHA
While Metabolix seems to be quiet these days (and people are still waiting for any production updates from the company…), Meredian on the other hand, has been churning out several news recently, the latest one is its merger with sister company, DaniMer Scientific. The companies now have merged under a wholly-owned subsidiary Meredian Holdings Group Inc.
The Boards of the two companies believe the restructure will increase the size and market awareness of Meredian and DaniMer, which will make the combined enterprise more attractive and provide a natural vertical integration into their supply chain. Meredian is known as a producer of the biodegradable PHA (polyhydroxyalkanoate) bioplastic resins while DaniMer is more known for development, marketing and sales of renewable-based products.
Last year, DaniMer has partnered with Henkel on the development of hotmelt bio-based adhesives, and in 2012 it has partnered also with Myriant and DuPont Tate & Lyle on bio-based label adhesives.
The recent press release noted that the merger will provide the companies with a broader range of services to offer clients and higher levels of efficiencies and shared resources.Upon the merger, the shareholders from Meredian and DaniMer all hold equal shares of both companies.
Meredian recently hired a new chief financial officer to help the company explore financial options including a possible IPO (initial public offering). Meredian has engaged Piper Jaffray for the potential IPO and noted that it plans to go through the offering when the US Security and Exchange Commission (SEC) completes its review of the IPO submission.
Meredian has a manufacturing facility in Bainbridge, Georgia, which has the capability to produce 30 ktpa of PHA at full capacity. The last the blog heard is that the facility is reportedly been producing 400 pounds/week of PHA, and expects to increase
You mentioned that they "filed for an IPO". Intending to file for an IPO is much like "engaged to be engaged" from Animal House. MBLX's financing or lack of financing will have to be resolved by July 31 and announced when they file the Q by August 14. This in all likelihood will precede any specific terms of a prospectus filed by Meredian with an "e".
Far be it for me to make things personal but a little research from the industry such as Doris De Guzman greenchemicalsblog should provide an indication of the source of my initial topic. I do apologize for my spelling error, if that was the reason why you failed to find the source. Incidently if you look at their CFO and his credentials you will see why he has been hired. Again I would suggest that anyone who takes a position in a speculative stock do their research and not rely on unverified sources from the industry.
Sentiment: Strong Sell
Meredian has NOT filed for an IPO. Their news feed from their website makes no mention of it. Nothing has been filed with the SEC. Maybe if he learned to spell the name correctly--it's Merdian with and e and not an i he might be more credible. Meredian JUST hired a new CFO last week--hence an IPO would not come immediately. Totally fabricated information.
I find it amusing that my comment (which is purely a comment on a competitor which is in the public arena) is getting thumbs down. It is what it is. The world is moving on. MBLX had this years ago and blew it. On the positive side Meredian are still using 1st generation Canola Seeds, but they are producing solvent free processing that has provided them with FDA approval, which is something that MBLX failed to achieve. On the back of that I am back shorting the stock and expect it to test $0.50c with or without funding shortly.
Sentiment: Strong Sell